

APAC Community Call

APAC 2022 Recap and Year Closing

December 15, 2022



Agenda

- OHDSI News
- Holiday Surprise!
- APAC 2022 Highlights
- APAC 2023 Preview



OHDSI News

Post-event page for APAC Symposium has been setup!

2022 APAC OHDSI Symposium

Nov. 12 - 13 • Taipei Medical University



There has been exciting progress and growth within the OHDSI Asia-Pacific (APAC) community, and that was shown during the 2022 APAC Symposium, held Nov. 12-13 at the Taipei Medical Center. Thank you to Taiwan Chapter lead Jason Hsu and the full team for putting this terrific two-day event together. Following a full-day tutorial on "An Introductory Journey from Data to Evidence," there was a one-day conference that included three featured talks:

- · Envisioning of OHDSI Global & OHDSI APAC
- The Implication Experiences in OHDSI Region
- The Challenges of Research in OHDSI APAC



Holiday Surprise!





First OHDSI APAC Study published in JAMA Network Open!





Original Investigation | Cardiology

Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort

Yuan Lu, ScD; Mui Van Zandt, BS; Yun Liu, PhD; Jing Li, MS; Xialin Wang, MS; Yong Chen, PhD; Zhengfeng Chen, MBBS, MMed; Jaehyeong Cho, PhD; Sreemanee Raaj Dorajoo, PhD; Mengling Feng, PhD; Min-Huei Hsu, MD, PhD; Jason C. Hsu, PhD; Usman Iqbal, PharmD, MBA, PhD; Jitendra Jonnagaddala, PhD; Yu-Chuan Li, MD, PhD; Siaw-Teng Liaw, MBBS, PhD; Hong-Seok Lim, MD, PhD; Kee Yuan Ngiam, MBBS, MMed; Phung-Anh Nguyen, PhD; Rae Woong Park, MD, PhD; Nicole Pratt, PhD; Christian Reich, MD, PhD; Sang Youl Rhee, MD; Selva Muthu Kumaran Sathappan, MSc; Seo Jeong Shin, PhD; Hui Xing Tan, MTech; Seng Chan You, MD, PhD; Xin Zhang, MS; Harlan M. Krumholz, MD, SM; Marc A. Suchard, MD, PhD; Hua Xu, PhD

Abstract

IMPORTANCE More than 1 billion adults have hypertension globally, of whom 70% cannot achieve their hypertension control goal with monotherapy alone. Data are lacking on clinical use patterns of dual combination therapies prescribed to patients who escalate from monotherapy.

OBJECTIVE To investigate the most common dual combinations prescribed for treatment escalation in different countries and how treatment use varies by age, sex, and history of cardiovascular disease.

Key Points

Question What are the most common antihypertensive dual combinations prescribed to patients who escalate from monotherapy in clinical practice, and how do the combinations differ by country and patient demographic subgroup?



APAC newsletters launched!



2022 Q2 APAC Newsletter


This first edition of the OHDSI APAC Newsletter features mid-year updates from our six regional chapters, upcoming events and more! #JoinTheJourney

Community Updates

Where Have We Been?

- ▶ We are proud to announce that the first OHDSI APAC community study, Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort, was published in JAMA Network Open last March! The study aimed to investigate dual combination therapies frequently used in hypertension and how they vary across different countries and demographic groups. Many thanks to our colleagues who contributed to this incredible multinational study!
- ▶ Regional chapter leaders from Taiwan, Singapore, Australia, Japan, Korea and China presented their mid-year updates at our latest community call.

 Watch the video to learn more about the developments from each chapter!





2022 Q3 APAC Newsletter

This second edition of the OHDSI APAC Newsletter features the upcoming 2022 OHDSI APAC Symposium, initiation of a new regional chapter and more! #JoinTheJourney

Community Updates

Where Have We Been?

- ▶ Please welcome our latest APAC regional chapter, India!
 - Since 2016, the OHDSI APAC community has been expanding through various countries in the region. In addition to the existing regional chapters - Korea, China, Japan, Australia, Singapore and Taiwan - we are excited to announce that the seventh regional chapter, India, has been officially initiated. Please welcome India to the community! Jointly founded by our colleagues from Global Value Web and JSS Academy of Higher Education & Research (AHER), OHDSI India is now actively searching for collaborators. Please check out this fiver for more information.





New regional chapter, India!





4 research initiatives selected and showcased!



Seng Chan You

Characterization of Health by OHDSI AP chapter to identify Temporal Effect of the Pandemic (CHAPTER)



Celine Chui and team

Comparison of mortality, morbidities & healthcare resources utilisation between patients with and without a diagnosis of COVID-19



Nicole Pratt

Treatment, utilisation and safety of medicines for Multiple Sclerosis (TELEMUS)




Chungsoo Kim

Data quality of OHDSI APAC: CDM Inspection study



• Live presentations from speakers around the world!





First in-person APAC symposium in Taiwan!





• In-person OHDSI/OMOP tutorial in Singapore!





APAC 2023 Preview

- Community calls will change from bi-weekly to monthly
- Formation of APAC research workgroup
 - Workgroup to make individual APAC study efforts into a group effort
 - Individual bi-weekly study calls will be merged into single monthly calls
- 2023 OHDSI APAC Symposium will be held in Sydney
 - July 13-14, immediately after Medinfo 2023 (July 8-12)
 - Main conference on Day 1, tutorials and mini-studython on Day 2
 - More info coming soon!



The Journey Continues...

Tutorials in local languages



- Education working group
- Glossary of terms localization



